Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CLASh | TSXV | CAD | Delayed | |
CLAZF | OTC Markets | USD | Delayed | |
CLASh | CBOE Canada | CAD | Real-time |
For the nine months ended 30 September 2021,Claritas Pharmaceuticals Inc revenues was not reported. Netloss before extraordinary items totaled $1.3M vs. income of$1.1M. Net loss reflects Finance income decrease of 76% to$709K (income), Finance expenses increase from $245K to$749K (expense). Basic Earnings per Share excludingExtraordinary Items decreased from $0.04 to -$0.04.
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -0.51 | -0.55 | -0.16 | 1.72 |
Net Income | 0.18 | -1.94 | -2.3 | -0.65 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Assets | 11.02 | 11.15 | 8.11 | 10.45 |
Total Liabilities | 7.74 | 8.39 | 7.93 | 8.94 |
Total Equity | 3.28 | 2.76 | 0.18 | 1.51 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -0.47 | -0.19 | -0.32 | -0.31 |
Cash From Investing Activities | 0 | 0 | 0 | 0 |
Cash From Financing Activities | 0.47 | 0.47 | 0.35 | 0.28 |
Net Change in Cash | -0 | 0.28 | 0.02 | -0.03 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review